CD274 and neoplasm: Therefore, even if mutations in the LKB1 gene are generally correlated with resistance to PD-1/PD-L1 and CTLA4 inhibitors, the concomitant use of other targeted agents could reverse this resistance, making also this tumor eligible for immunotherapy.